Allarity Therapeutics A / S develops various therapeutic candidates for the treatment of cancer using complementary drug-specific diagnostics (cDx) generated by its drug response prediction technology. The company is headquartered in Horsholm, Denmark. Show more

123 E. TARPON AVE., TARPON SPRINGS, FL, UNITED STATES, 34689, Tarpon Springs, FL, 34689, USA

BIOTECHNOLOGY

HEALTHCARE

Market Cap

20.08M

52 Wk Range

$0.77 - $1.84

Previous Close

$1.26

Open

$1.29

Volume

81,941

Day Range

$1.22 - $1.35

Enterprise Value

25.35M

Cash

16.98M

Avg Qtr Burn

-2.564M

Insider Ownership

4.19%

Institutional Own.

8.05%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Stenoparib (2X-121) (PARP Tankyrase Inhibitor) Details Platinum Resistant Or Platinum-Ineligible Ovarian Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Stenoparib (2X-121) (PARP Tankyrase Inhibitor) Details Relapsed Small Cell Lung Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Stenoparib (2X-121) (PARP Tankyrase Inhibitor) Details Ovarian Cancer (2+ Lines Of Therapy)	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.